Phase 3 Trial Results with Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Subjects with Moderate-to-Severe Systemic Lupus Erythematosus

被引：0

作者：

Merrill, Joan T. ^{[1
]}

Martin, Renee S. ^{[2
]}

Shanahan, William ^{[2
]}

Scheinberg, Morton ^{[3
]}

Kalunian, Kenneth C. ^{[4
]}

Wofsy, David ^{[5
]}

机构：

[1] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA

[2] Anthera, Hayward, CA USA

[3] Ctr Clin Immunol, Dept Immunol, Sao Paulo, SP, Brazil

[4] UCSD Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA USA

[5] UCSF, Rheumatol, San Francisco, CA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

888

引用

页数：2

共 50 条

[21] EPRATUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM EMBLEM™, A PHASE IIB STUDY
Gordon, Caroline
Kalunian, K.
Petri, M.
Strand, V.
Kilgallen, B.
Barry, A.
Wallace, D.
[J]. RHEUMATOLOGY, 2012, 51 : 25 - 25
[22] Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)
Stohl, William
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (06) : 623 - 633
[23] Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Lazarus, Mark
Newcombe, Paul
Furie, Richard A.
Brohawn, Philip
White, Wendy
Sinibaldi, Dominic
Ferrari, Nicola
Tummala, Raj
Al-Mossawi, Hussein
Vital, Edward
Morand, Eric F.
Muthas, Daniel
Ramaswamy, Madhu
[J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 714 - 715
[24] Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus
Mukul Minocha
Jiewei Zeng
Jeroen K. Medema
Ahmed A. Othman
[J]. Clinical Pharmacokinetics, 2018, 57 : 1185 - 1198
[25] Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus
Minocha, Mukul
Zeng, Jiewei
Medema, Jeroen K.
Othman, Ahmed A.
[J]. CLINICAL PHARMACOKINETICS, 2018, 57 (09) : 1185 - 1198
[26] Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study
Tsuru, Tomomi
Tanaka, Yoshiya
Kishimoto, Mitsumasa
Saito, Kazuyoshi
Yoshizawa, Seiji
Takasaki, Yoshinari
Miyamura, Tomoya
Niiro, Hiroaki
Morimoto, Shinji
Yamamoto, Junichi
Lledo-Garcia, Rocio
Shao, Jing
Tatematsu, Shuichiro
Togo, Osamu
Koike, Takao
[J]. MODERN RHEUMATOLOGY, 2016, 26 (01) : 87 - 93
[27] B- Cell Activating Factor Promoter Polymorphisms in Egyptian Patients with Systemic Lupus Erythematosus
Zayed, Rania A.
Sheba, Hala F.
Elazaem, Mennat Allah K. Abo
Elsaadany, Zainab A.
Elmessery, Lobna O.
Mahmoud, Jelan A.
Rahman, Dalia R. Abdel
Abdou, Faten R.
[J]. ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2013, 43 (03): : 289 - 294
[28] Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Carter, Lucy M.
Isenberg, David A.
Ehrenstein, Michael R.
[J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S663 - S664
[29] Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus
Friebus-Kardash, Justa
Branco, Leonore
Ribi, Camillo
Chizzolini, Carlo
Huynh-Do, Uyen
Dubler, Denise
Roux-Lombard, Pascale
Dolff, Sebastian
Kribben, Andreas
Eisenberger, Ute
Trendelenburg, Marten
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (01) : 54 - 64
[30] IMMUNE COMPLEXES CONTAINING SERUM B-CELL ACTIVATING FACTOR AND IMMUNOGLOBULIN G CORRELATE WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Friebus-Kardash, J.
Branco, L.
Ribi, C.
Chizzolini, C.
Huynh-Do, U.
Dubler, D.
Kribben, A.
Eisenberger, U.
Trendelenburg, M.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S29 - S29

← 1 2 3 4 5 →